Reference
Zimmermann MR, et al. A Cost-Effectiveness Analysis of Voretigene Neparvovec for Vision Loss Due to Biallelic Rpe65-Mediated Inherited Retinal Disease. 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND25, 19 May 2018. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/81795?pdfid=53910
Rights and permissions
About this article
Cite this article
Voretigene neparvovec too costly for rare retinal disease?. PharmacoEcon Outcomes News 805, 36 (2018). https://doi.org/10.1007/s40274-018-5038-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5038-4